Luteal phase sertraline treatment for premenstrual dysphoric disorder - Results of a double-blind, placebo-controlled, crossover study
Luteal phase sertraline treatment for premenstrual dysphoric disorder - Results of a double-blind, placebo-controlled, crossover study
复制标题
DOI：
10.1001/archfami.8.4.328
复制
发表时间：
1999-07-01
期刊：
影响因子：
--
通讯作者：
Sulak, PJ
中科院分区：
文献类型：
--
作者：
Jermain, DM;Preece, CK;Sulak, PJ
Objective: To test the efficacy of late-luteal phase dosing of sertraline hydrochloride in women with moderate-to-severe premenstrual dysphoric disorder. This highly prevalent disorder often causes significant psychosocial impairment.Design Double-blind, crossover trial of each 2-menstrual cycle of baseline, sertraline treatment, and placebo. Randomization to sertraline treatment vs placebo occurred after a 2-cycle, drug-free period.Setting: A large outpatient multispecialty clinic in central Texas.Patients: Fifty-seven women aged 19 to 49 years with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of premenstrual dysphoric disorder.Interventions: Late-luteal phase treatment with sertraline hydrochloride in daily doses of 50 mg (cycle 1) followed by 100 mg (cycle 2) vs placebo.Main Outcome Measures: The 22-item calendar of premenstrual experiences was completed daily and constituted the primary outcome measure, consisting of a total score and behavioral and physical factor scores.Results: A repeated-measures analysis of variance for crossover designs found a significant beneficial effect from sertraline treatment in improving the calendar of premenstrual experiences total (P
